118 related articles for article (PubMed ID: 38040273)
1. Fusion expression, purification, and characterization of cytokeratin 19 fragments in E. coli for enhanced stability in diagnostic applications.
Liu Y; Zhu P; Ji C; Dong L; Yi W
Protein Expr Purif; 2024 Mar; 215():106410. PubMed ID: 38040273
[TBL] [Abstract][Full Text] [Related]
2. Biochemical analysis of cytokeratin fragment 21-1 concentration and expression of cytokeratin 19 in oral potentially malignant disorders.
Rathore AS; Katyal S; Jain A; Shetty DC
J Cancer Res Ther; 2020; 16(3):452-457. PubMed ID: 32719250
[TBL] [Abstract][Full Text] [Related]
3. A sensitive label-free electrochemical immunosensor for detection of cytokeratin 19 fragment antigen 21-1 based on 3D graphene with gold nanopaticle modified electrode.
Zeng Y; Bao J; Zhao Y; Huo D; Chen M; Yang M; Fa H; Hou C
Talanta; 2018 Feb; 178():122-128. PubMed ID: 29136801
[TBL] [Abstract][Full Text] [Related]
4. [Value of tumor markers series of hydrothorax in differential diagnosis of pleural effusion].
Liu YQ; Zhang HL; Gao WJ; Lan X; Yuan BJ; Zou JM
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Jan; 26(1):34-8. PubMed ID: 18302890
[TBL] [Abstract][Full Text] [Related]
5. Prediction of Pleural Invasion in Challenging Non-Small-Cell Lung Cancer Patients Using Serum and Imaging Markers.
Zhu K; Chen L; He C; Lang Y; Kong X; Qu C; Xu S
Dis Markers; 2020; 2020():6430459. PubMed ID: 32089756
[TBL] [Abstract][Full Text] [Related]
6. Electrochemiluminescent immunoassay for the lung cancer biomarker CYFRA21-1 using MoO
Meng X; Chen X; Wu W; Zheng W; Deng H; Xu L; Chen W; Li Z; Peng H
Mikrochim Acta; 2019 Nov; 186(12):855. PubMed ID: 31784817
[TBL] [Abstract][Full Text] [Related]
7. Non-invasive bioassay of Cytokeratin Fragment 21.1 (Cyfra 21.1) protein in human saliva samples using immunoreaction method: An efficient platform for early-stage diagnosis of oral cancer based on biomedicine.
Jafari M; Hasanzadeh M
Biomed Pharmacother; 2020 Nov; 131():110671. PubMed ID: 32853907
[TBL] [Abstract][Full Text] [Related]
8. [The evaluation of the newly produced assay kit for the cytokeratin fragment, "ball ELSA CYFRA21-1"].
Kimura Y; Ata M; Nakamura S; Fujii T; Kawamura T; Tanada S; Hamamoto K
Kaku Igaku; 1994 Feb; 31(2):199-206. PubMed ID: 7509886
[TBL] [Abstract][Full Text] [Related]
9. [The clinical signifinace of CEA, Cyfra21-1 and SCC in laryngeal carcinoma's clinicopathological parameters].
Rao LH; Zhang L; Tian L; Yan JR; Xiang XY; Yu FB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Aug; 31(15):1182-1186. PubMed ID: 29798354
[No Abstract] [Full Text] [Related]
10. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China.
Ma L; Xie XW; Wang HY; Ma LY; Wen ZG
Asian Pac J Cancer Prev; 2015; 16(12):4891-4. PubMed ID: 26163610
[TBL] [Abstract][Full Text] [Related]
11. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of hTFF2 in the pET system and its in vitro pharmacological characterization.
Sun Y; Wu W; Wang L; Liang G; Zhang Y; Lv S; Wang Z; Wang S; Peng X
Biomed Pharmacother; 2010 May; 64(5):343-7. PubMed ID: 20074900
[TBL] [Abstract][Full Text] [Related]
13. A sandwich-type electrochemical immunoassay for ultrasensitive detection of non-small cell lung cancer biomarker CYFRA21-1.
Zeng Y; Bao J; Zhao Y; Huo D; Chen M; Qi Y; Yang M; Fa H; Hou C
Bioelectrochemistry; 2018 Apr; 120():183-189. PubMed ID: 29289826
[TBL] [Abstract][Full Text] [Related]
14. Electrochemical ultrasensitive detection of CYFRA21-1 using Ti
Cheng J; Hu K; Liu Q; Liu Y; Yang H; Kong J
Anal Bioanal Chem; 2021 Apr; 413(9):2543-2551. PubMed ID: 33576855
[TBL] [Abstract][Full Text] [Related]
15. [Diagnostic value of serum tumor markers CEA, CYFRA21-1, SCCAg, NSE and ProGRP for lung cancers of different pathological types].
Gao J; Zhang L; Peng K; Sun H
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Jun; 42(6):886-891. PubMed ID: 35790439
[TBL] [Abstract][Full Text] [Related]
16. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
17. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
19. The application of CYFRA21-1 in cervical lesions screening in high-risk human papillomavirus infected women.
Yang-Chun F; Jia Y; Yan-Chun H
Ginekol Pol; 2016; 87(9):617-620. PubMed ID: 27723067
[TBL] [Abstract][Full Text] [Related]
20. The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
Yang J; Tang A; Ma J; Sun X; Ming L
Scand J Clin Lab Invest; 2019; 79(1-2):71-74. PubMed ID: 30727773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
